1. Metagenomic Analysis of the Tumour Microbiota–Mycobiota–Virome Axis in EBV-Positive Nasopharyngeal and HPV-Positive Oropharyngeal Cancer

This pioneering metagenomic study investigates the local tumour microbiota–virome–mycobiota axis in patients with EBV-associated nasopharyngeal cancer and HPV-associated oropharyngeal cancer. The aim is to identify microbial patterns linked to viral dynamics, treatment response, and toxicity through comprehensive analysis of clinical samples. This may help elucidate upstream microbial factors influencing susceptibility to viral infection and the pathogenesis of these cancers.

2. Investigating Fluoxetine as a Radiosensitiser in Glioblastoma

Fluoxetine, a widely used antidepressant, exhibits selective cytotoxicity against glioblastoma through EGFR inhibition and disruption of DNA repair pathways. Preclinical models demonstrate that fluoxetine enhances the efficacy of radiotherapy and temozolomide, increasing DNA damage and tumour cell death. This project aims to investigate the underlying mechanisms and therapeutic potential of fluoxetine as a novel radiosensitising agent in glioblastoma.

3. Modulation of Gut Microbiota to Enhance Radiotherapy Outcomes

Alteration of gut microbiota has been shown to improve tumour control following radiotherapy. This effect is associated with enhanced anti-tumour immunity, beneficial metabolite production, and favourable shifts in microbial composition. We aim to explore the potential of high-fibre dietary supplementation, defined microbial consortia, or microbiota-derived metabolites as adjunct strategies to boost radiotherapy efficacy.